The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

CompletedOBSERVATIONAL
Enrollment

72

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

July 1, 2023

Study Completion Date

April 1, 2024

Conditions
Pancreatic Cancer
Interventions
DRUG

Surufatinib combine immune checkpoint inhibitor

"Before drug use demographics, blood markers, pathology information# and enhanced CT features.~Chemotherapy regimens that were combined with surufatinib included AG or FOLFIRINOX regimens. The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxalip"

DRUG

AG/FOLFIRINOX

"Before drug use demographics, blood markers, pathology information# and enhanced CT features.~The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxaliplatin (85 mg/m2), irinotecan (180 mg/m2), leucovorin (400 mg/m2), and 5-fluorouracil (400 mg/m2 bolus, 2400 mg/m2 continuous intravenous infusion for 46 hours) every 14 days. Both the AG and FOLFIRINOX regimens required completion of 6 cycles or until disease progression or unacceptable toxicity."

Trial Locations (1)

310000

Zhejiang Province Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Luo Cong

OTHER